Potential hit for Cipla from US animal health patent case?
This article was originally published in Scrip
Executive Summary
A US appeals court has upheld a previous order against Cipla in a case concerning the Indian firm's generic version of FrontLine Plus, a companion animal antiparasitic brand marketed by Sanofi's animal health division Merial.